Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375379 | 1.00 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4MCHR1 | |
| SCHEMBL14287076 | 0.90 | GRIA1 (0.32) | GRIA1GRIA2GRIA3GRIA4MCHR1 | |
| SCHEMBL14287075 | 0.90 | GRIA1 (0.35) | GRIA1GRIA2GRIA3GRIA4GRM2 | |
| SCHEMBL7357256 | 0.89 | MEN1 (0.38) | GRIA1GRIA2GRIA3GRIA4MCHR1 | |
| SCHEMBL8103012 | 0.89 | MEN1 (0.38) | GRIA1GRIA2GRIA3GRIA4MCHR1 | |
| SCHEMBL13592439 | 0.89 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL13592447 | 0.89 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL4373619 | 0.89 | GRIA1 (0.37) | GRIA1GRIA2GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL4373620 | 0.89 | GRIA1 (0.37) | GRIA1GRIA2GRIA3GRIA4SMN1; SMN2 | |
| SCHEMBL7353277 | 0.89 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1736468-A2 | Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation | NeuroSearch A/S (DK) | 2006-12-27 | — | — | EP | claimed |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | GROENBORG METTE | 2006-10-12 | — | — | US | claimed |
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2006-04-13 | — | — | US | claimed |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | NEUROSEARCH A/S | 2004-07-22 | — | — | US | claimed |
| US-6727260-B2 | USING COMPOUNDS CAPABLE OF INHIBITING THE ACTIVITY OF A PROTON-GATED CATION CHANNEL IN THERAPY OR ALEVIATION OF DISEASES OR DISORDERS ASSOCIATED WITH, OR MEDIATED BY A DROP IN EXTRACELLULAR PH | NEUROSEARCH A/S (DK) | 2004-04-27 | — | — | US | claimed |
| JP-2003520851-A | — | — | 2003-07-08 | — | — | JP | claimed |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | ANIONA APS (DK) | 2003-02-27 | — | — | US | claimed |
| EP-1255734-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NeuroSearch A/S (DK) | 2002-11-13 | — | — | EP | claimed |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | AROS PHARMA APS (DK) | 2002-05-16 | — | — | US | claimed |
| EP-1183025-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2002-03-06 | — | — | EP | claimed |
| WO-2001055110-A1 | ISATINE DERIVATIVES WITH NEUROTROPHIC ACTIVITY | NEUROSEARCH A/S (DK) | 2001-08-02 | — | — | WO | claimed |
| WO-2000071102-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2000-11-30 | — | — | WO | claimed |
| US-7595336-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2009-09-29 | — | — | US | disclosed |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7288653-B2 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7282511-B2 | Isatine derivatives with neurotrophic activity | NEUROSEARCH A/S (DK) | 2007-10-16 | — | — | US | disclosed |
| EP-0781284-A1 | INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008494-A1 | INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1996-03-21 | — | — | WO | disclosed |
| EP-0698025-A1 | AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH | NEUROSEARCH A/S (DK) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026747-A1 | AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH | NEUROSEARCH A/S (DK) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | GRIA1 393/4885GRIA2 266/4885GRIA3 251/4885 |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | GRIA1 393/4885GRIA2 266/4885GRIA3 251/4885 |
| US-20060229311-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | GRIA1 2063/4885GRIA2 1785/4885GRIA3 653/4885 |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | ASIC1, ASIC3, TRPM4 | GRIA1 279/4885GRIA2 210/4885GRIA3 216/4885 |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | GRIA1 393/4885GRIA2 266/4885GRIA3 251/4885 |
| US-20030040518-A1 | Isatine derivatives with neurotrophic activity | BDNF, NTRK2, NGF | GRIA1 2063/4885GRIA2 1785/4885GRIA3 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.